Scope of this summary
Adolescents and adults with a new, persistent, progressive or unexplained symptom or finding that could represent cancer. This page is deliberately limited to symptom recognition, selection of a site-specific diagnostic route, tissue confirmation principles and reliable result follow-up. It is not a screening schedule, an organ-specific test algorithm or a substitute for emergency stabilization.
The Bottom Line
- Start with the symptom, its duration and the affected organ system. NCI lists persistent breast, bladder, bowel, neurologic, skin, constitutional and other changes as reasons for clinical assessment while emphasizing that these symptoms have many noncancer causes.
- Distinguish screening in a person without related symptoms from diagnostic evaluation of a symptom or finding; organ-specific guidance controls the next step once a breast mass, hematuria, iron-deficiency anemia or another defined presentation is identified.
- Use the history and examination to identify the likely anatomical site and select a focused diagnostic test or specialist rather than treating a broad tumor-marker panel as a universal cancer screen.
- NCI describes biopsy as the preferred method for confirming or excluding cancer when tissue can be obtained; imaging can localize disease and guide sampling, but the site-specific team must choose a technique that preserves useful diagnostic and staging information.
- Close the loop on every ordered test and referral. AHRQ defines closure as a result being sent, received, acknowledged and acted on, including communication to the patient in language they understand.
Practical clinical workflow
1
Document onset, persistence, progression, pain, bleeding, weight or appetite change, prior testing, relevant exposure and functional effect, then perform an anatomically focused examination.
2
Assess physiologic stability and organ function before outpatient investigation; an unstable patient or an acute neurologic, bleeding, obstructive or respiratory presentation follows the applicable emergency protocol rather than this ambulatory framework.
3
Select the named US pathway that matches the finding鈥攆or example AUA hematuria, ACR breast or adnexal imaging, or AGA iron-deficiency evaluation鈥攁nd record the clinical question the test or referral is intended to answer.
4
Explain the planned sequence and uncertainty, including that an initial result answers a bounded question and may not explain a persistent or progressive symptom.
5
Review completion and results against the original concern; assign responsibility for missed, indeterminate or discordant testing and document the next action and patient communication.
Safety boundaries and escalation
- Rapid neurologic loss, major hemorrhage, acute obstruction or cardiorespiratory compromise requires emergency assessment rather than routine outpatient referral.
- Do not describe one normal laboratory, imaging or screening result as excluding every cancer; interpret it only within the population, organ and question for which that test is validated.
- Use the relevant organ-specific source before attributing persistent bleeding or a new mass to a benign explanation, because the threshold and test sequence differ by presentation.
- Document and communicate incidental, abnormal or indeterminate findings and verify that recommended repeat testing, biopsy or specialist review is completed.
Localization
This page therefore stops at symptom-led diagnostic safety and named organ-specific sources; health-system routing must not be presented as a universal referral clock.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- National Cancer InstituteSymptoms of Cancerupdated 2019-05-16 路 accessed 2026-08-20view source
- National Cancer InstituteCancer DiagnosisSEER Training Module 路 accessed 2026-08-20view source
- Agency for Healthcare Research and QualityCurrent State of Diagnostic Safety: Implications for Research, Practice, and PolicyIssue Brief 路 accessed 2026-08-20view source
- American Urological Association and Society of Urodynamics, Female Pelvic Medicine & Urogenital ReconstructionMicrohematuria: AUA/SUFU Guidelinepublished 2020; amended 2025 路 published 2020-10-01 路 updated 2025-02-01 路 accessed 2026-08-20view source
- American College of RadiologyACR Appropriateness Criteria: Palpable Breast Massesrevised 2022 路 published 2022-10-01 路 accessed 2026-08-20view source
- American Gastroenterological AssociationGastrointestinal Evaluation of Iron Deficiency AnemiaDOI 10.1053/j.gastro.2020.06.046 路 published 2020-08-15 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.